Increasing IL-18BP amount/activity (a therapeutic option already clinically validated to treat a rare systemic auto-inflammatory disease)44 could represent an interesting therapeutic perspective to treat MASLD/MASH as well as gut microbiota dysbiosis. This evidence concerns the gene IL18BP and metabolic dysfunction-associated steatohepatitis.